Diversification Fails To Protect Merck KGaA From Industry Pressures
This article was originally published in The Pink Sheet Daily
Merck KGaA plans to cut headcount and reduce costs, although employees are to be asked first to identify pragmatic cost-saving strategies.
You may also be interested in...
Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.